GSK suffers Avandia UK blow

GlaxoSmithKline’s diabetes drug Avandia should be pulled from sale because of concerns about heart risks, British drug regulators will today say ahead of a special European meeting on the drug's safety. The strong line from safety experts in the drugmaker’s home market is a fresh blow to a medicine that was once Glaxo’s second biggest seller but has become a liability since being linked to increased heart attack risk in 2007.